Clinical Trial Update: A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating ALN-6400 in healthy volunteers and patients with Hereditary Hemorrhagic Telangiectasia is currently recruiting in Phase 1 and Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• ALN-6400

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Hereditary Hemorrhagic Telangiectasia | Phase 1, Phase 2 | Status: RECRUITING